[go: up one dir, main page]

MX2016004741A - Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. - Google Patents

Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.

Info

Publication number
MX2016004741A
MX2016004741A MX2016004741A MX2016004741A MX2016004741A MX 2016004741 A MX2016004741 A MX 2016004741A MX 2016004741 A MX2016004741 A MX 2016004741A MX 2016004741 A MX2016004741 A MX 2016004741A MX 2016004741 A MX2016004741 A MX 2016004741A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
analgesic agent
trpa1 antagonist
patent application
present patent
Prior art date
Application number
MX2016004741A
Other languages
English (en)
Inventor
Srinivas Gullapalli
Praveen Kumar Gupta
Maulik Nitinkumar Gandhi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2016004741A publication Critical patent/MX2016004741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud de patente se relaciona con una composición farmacéutica que comprende un antagonista de TRPA1 y un agente analgésico. Particularmente, la presente solicitud de patente proporciona una composición farmacéutica que comprende un compuesto de tienopirimidinodiona como antagonista de TRPA1 y un agente analgésico; y el uso de tal composición para tratar el dolor en un sujeto.
MX2016004741A 2013-10-15 2014-10-14 Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. MX2016004741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3247MU2013 2013-10-15
PCT/IB2014/002501 WO2015056094A2 (en) 2013-10-15 2014-10-14 Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent

Publications (1)

Publication Number Publication Date
MX2016004741A true MX2016004741A (es) 2016-07-26

Family

ID=52146548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004741A MX2016004741A (es) 2013-10-15 2014-10-14 Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.

Country Status (9)

Country Link
US (1) US9532988B2 (es)
EP (1) EP3057583A2 (es)
JP (1) JP2016537322A (es)
CN (1) CN105813638A (es)
AU (1) AU2014335868A1 (es)
CA (1) CA2926389A1 (es)
MX (1) MX2016004741A (es)
RU (1) RU2016115093A (es)
WO (1) WO2015056094A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) * 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017059088A1 (en) * 2015-09-30 2017-04-06 George Edward Hoag Topical analgesic pain relife formulations, manufacture and methods of use thereof
GB201520057D0 (en) * 2015-11-13 2015-12-30 Ucl Business Plc New therapeutic approaches for demyelinating diseases such as multiple sclerosis
CN109310683A (zh) 2016-04-07 2019-02-05 杜克大学 用于消毒和麻醉的trpv4和trpa1的小分子双重抑制剂
CN106243096B (zh) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
CN112438970B (zh) * 2020-11-20 2023-04-21 南方医科大学南方医院 米那普仑或/和米那普仑的药用盐的新用途
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
CN116999560A (zh) * 2022-04-30 2023-11-07 武汉思瓴生物科技有限公司 可治疗疼痛的药物组合及其应用
CN115778945A (zh) * 2023-01-31 2023-03-14 广州帝奇医药技术有限公司 一种组合物及其在制备治疗神经性疼痛药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
ES2436225T3 (es) 2005-12-22 2013-12-27 Hydra Biosciences, Inc. Inhibidores TRPA1 para tratamiento del dolor
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
CN103751194B (zh) 2007-06-22 2018-01-05 海德拉生物科学公司 用于治疗病症的方法和组合物
CN101959511A (zh) 2008-01-04 2011-01-26 雅培制药有限公司 Trpa1拮抗剂
WO2009144548A1 (en) 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
WO2010004390A1 (en) 2008-06-17 2010-01-14 Glenmark Pharmaceuticals, S.A. Quinazoline dione derivatives as trpa1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
CA2756534A1 (en) 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
WO2010109329A1 (en) * 2009-03-23 2010-09-30 Glenmark Pharmaceuticals, S.A. Furopyrimidinedione derivatives as trpa1 modulators
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
WO2010125469A1 (en) 2009-04-29 2010-11-04 Glenmark Pharmaceuticals, S.A. Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators
US8614201B2 (en) 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
JP2013507364A (ja) 2009-10-07 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 新規なｔｒｐａ１アンタゴニスト
CA2820448A1 (en) 2010-12-20 2012-06-28 Glenmark Pharmaceuticals, S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists

Also Published As

Publication number Publication date
US20150105406A1 (en) 2015-04-16
EP3057583A2 (en) 2016-08-24
CA2926389A1 (en) 2015-04-23
US9532988B2 (en) 2017-01-03
JP2016537322A (ja) 2016-12-01
RU2016115093A (ru) 2017-11-21
AU2014335868A1 (en) 2016-05-05
WO2015056094A2 (en) 2015-04-23
CN105813638A (zh) 2016-07-27
WO2015056094A3 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2020004075A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
UA115357C2 (uk) Похідні піридин-4-ілу
WO2014153009A3 (en) Thiosaccharide mucolytic agents
NZ702415A (en) Methods for treating neutropenia using retinoid agonists
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
WO2014146111A3 (en) Analgesic compounds and methods of use
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
IN2013MU03428A (es)
EA201491769A1 (ru) Фармацевтическая композиция с фиксированной дозой, содержащая мометазон и азеластин